Cyclosporine for Ocular Inflammatory Diseases

Ophthalmology

Volumn 117, Issue 3, 2010, Pages 576-584

  Kaçmaz, R Oktay ^a,b   Kempen, John H ^c   Newcomb, Craig ^c   Daniel, Ebenezer ^c,d   Gangaputra, Sapna ^d,f   Nussenblatt, Robert B ^g   Rosenbaum, James T ^h   Suhler, Eric B ^h,i   Thorne, Jennifer E ^d,e   Jabs, Douglas A ^a,e   Levy Clarke, Grace A ^g,j   Foster, C Stephen ^b,k  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g NATIONAL EYE INSTITUTE   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ PORTLAND VA MEDICAL CENTER   (United States)

^j St Luke's Cataract and Laser Institute   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EYE INFLAMMATION; FEMALE; GINGIVA HYPERPLASIA; GROUPS BY AGE; HIRSUTISM; HUMAN; HYPERTENSION; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; LIVER ENZYME BLOOD LEVEL; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL EXPERT; MEDICAL RECORD REVIEW; MELANOMA; MONOTHERAPY; MUCOUS MEMBRANE PEMPHIGOID; MULTICENTER STUDY; MYCOBACTERIOSIS; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY FAILURE; SCHOOL CHILD; SCLERITIS; TREATMENT DURATION; TREATMENT OUTCOME; UVEITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MALE; MIDDLE AGED; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; RETROSPECTIVE STUDIES; SCLERITIS; TREATMENT OUTCOME; UVEITIS; YOUNG ADULT;

EID: 77049113738     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.08.010     Document Type: Article

References (41)

1. Jabs D.A., Rosenbaum J.T., Foster C.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130 (2000) 492-513
2. Okada A.A. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 13 (2005) 335-351
3. Krensky A.M., Vincenti F., and Bennett W.M. Immunosuppressants, Tolerogens, and Immunostimulants. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. (2006)
4. Stepkowski S.M. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med 2 (2000) 1-23
5. Nussenblatt R.B., Rodrigues M.M., Wacker W.B., et al. Cyclosporin A: inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest 67 (1981) 1228-1231
6. Nussenblatt R.B., Palestine A.G., and Chan C.C. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 96 (1983) 275-282
7. Hesselink D.A., Baarsma G.S., Kuijpers R.W., and van Hagen P.M. Experience with cyclosporine in endogenous uveitis posterior. Transplant Proc 36 suppl (2004) 372S-377S
8. Isnard Bagnis C., Tezenas du Montcel S., Beaufils H., et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 13 (2002) 2962-2968
9. Palestine A.G., Austin III H.A., Balow J.E., et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 314 (1986) 1293-1298
10. BenEzra D., Cohen E., Chajek T., et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc 20 suppl (1988) 136-143
11. Binder A.I., Graham E.M., Sanders M.D., et al. Cyclosporin A in the treatment of severe Behcet's uveitis. Br J Rheumatol 26 (1987) 285-291
12. Masuda K., Nakajima A., Urayama A., et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1 (1989) 1093-1096
13. Ozdal P.C., Ortac S., Taskintuna I., and Firat E. Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc Ophthalmol 105 (2002) 301-312
14. Ozyazgan Y., Yurdakul S., Yazici H., et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol 76 (1992) 241-243
15. Nussenblatt R.B., Palestine A.G., and Chan C.C. Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol 1 (1985) 369-382
16. Wakefield D., and McCluskey P. Cyclosporine: a therapy in inflammatory eye disease. J Ocul Pharmacol 7 (1991) 221-226
17. Nussenblatt R.B., Mittal K.K., Ryan S., et al. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol 94 (1982) 147-158
18. Le Hoang P., Girard B., Deray G., et al. Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc 20 suppl (1988) 128-130
19. Kiss S., Ahmed M., Letko E., and Foster C.S. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology 112 (2005) 1066-1071
20. Silverstein B.E., and Wong I.G. Reduction of cyclosporine dosage with ketoconazole in a patient with birdshot retinochoroidopathy. Am J Ophthalmol 125 (1998) 106-108
21. Becker M.D., Wertheim M.S., Smith J.R., and Rosenbaum J.T. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul Immunol Inflamm 13 (2005) 289-293
22. Secchi A.G., Tognon M.S., and Maselli C. Cyclosporine-A in the treatment of serpiginous choroiditis. Int Ophthalmol 14 (1990) 395-399
23. Araujo A.A., Wells A.P., Dick A.D., and Forrester J.V. Early treatment with cyclosporin in serpiginous choroidopathy maintains remission and good visual outcome. Br J Ophthalmol 84 (2000) 979-982
24. Michel S.S., Ekong A., Baltatzis S., and Foster C.S. Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology 109 (2002) 378-383
25. Murphy C.C., Greiner K., Plskova J., et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 123 (2005) 634-641
26. Walton R.C., Nussenblatt R.B., and Whitcup S.M. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology 105 (1998) 2028-2034
27. Nussenblatt R.B., Palestine A.G., Chan C.C., et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 112 (1991) 138-146
28. de Vries J., Baarsma G.S., Zaal M.J., et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 74 (1990) 344-349
29. Kempen J.H., Daniel E., Gangaputra S., et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol 15 (2008) 47-55
30. Lin D.Y., and Wei L.J. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 84 (1989) 1074-1078
31. Towler H.M., Whiting P.H., and Forrester J.V. Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation. Eye 4 (1990) 514-520
32. Vitale A.T., Rodriguez A., and Foster C.S. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology 103 (1996) 365-374
33. Tappeiner C., Roesel M., Heinz C., et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye 23 (2009) 1192-1198
34. McCarthy J.M., Dubord P.J., Chalmers A., et al. Cyclosporine A for the treatment of necrotizing scleritis and corneal melting in patients with rheumatoid arthritis. J Rheumatol 19 (1992) 1358-1361
35. Towler H.M., Lightman S.L., and Forrester J.V. Low-dose cyclosporin therapy of ocular inflammation: preliminary report of a long-term follow-up study. J Autoimmun 5 suppl (1992) 259-264
36. Kashani S., and Mearza A.A. Uses and safety profile of ciclosporin in ophthalmology. Expert Opin Drug Saf 7 (2008) 79-89
37. Kempen J.H., Gangaputra S., Daniel E., et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 146 (2008) 802-812
38. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 140 (2005) 509-516
39. Gangaputra S., Newcomb C.W., Liesegang T.L., et al. Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases. Ophthalmology 116 (2009) 2188-2198
40. Pasadhika S., Kempen J.H., Newcomb C.W., et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 148 (2009) 500-509
41. Pujari S.S., Kempen J.H., Newcomb C.W., et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 117 (2010) 356-365